{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:38:11Z","timestamp":1792550291936,"version":"4.5.0"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Linezolid has the potential to interact with some antidepressants, leading to serotonin syndrome. However, few empirical data support warnings for patients taking antidepressants to avoid linezolid.<\/jats:p><\/jats:sec>Objectives<\/jats:title>To examine the incidence of serotonin syndrome in patients receiving oral linezolid and how concomitant antidepressant treatment changes this risk.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This population-based, retrospective cohort study used linked administrative databases at ICES to collect data from outpatients 66 years or older in Ontario, Canada, who were prescribed oral linezolid for any duration from October 1, 2014, to January 1, 2021, with follow-up to 30 days (January 31, 2021).<\/jats:p><\/jats:sec>Exposures<\/jats:title>The use of antidepressants while receiving linezolid therapy vs no antidepressant use while receiving linezolid therapy.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was clinically significant serotonin syndrome based on a physician diagnosis, Sternbach criteria, or the Hunter Serotonin Toxicity Criteria within 30 days of starting oral linezolid treatment. Secondary outcomes were altered mental status, hospitalization, or death within 30 days of starting linezolid treatment.<\/jats:p><\/jats:sec>Results<\/jats:title>The study included 1134 patients (age ranges, 66-69 years for 225 patients [19.8%], 70-79 years for 473 patients [41.7%], and \u226580 years for 436 patients [38.4%]; 595 [52.5%] male) who were prescribed linezolid. Of 1134 patients, 215 (19.0%) were also taking antidepressants. Serotonin syndrome occurred in fewer than 6 patients (&amp;lt;0.5%). The number of serotonin syndrome cases were fewer in the antidepressant group. In a propensity score\u2013matched cohort, the adjusted risk difference for serotonin syndrome between the antidepressant group and the no antidepressant group was \u22121.2% (95% CI, \u22122.9% to 0.5%). There were similar rates of altered mental status, hospitalization, and death between the propensity score\u2013matched groups.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study of older patients who were prescribed linezolid, serotonin syndrome occurred rarely. Concurrent antidepressants did not significantly increase the risk of serotonin syndrome. These findings suggested that linezolid is likely safe for patients receiving antidepressants. Nevertheless, prescribers should remain vigilant for this potential drug interaction.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.47426","type":"journal-article","created":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T16:33:08Z","timestamp":1671467588000},"page":"e2247426","source":"Crossref","is-referenced-by-count":32,"title":["Association of Linezolid With Risk of Serotonin Syndrome in Patients Receiving Antidepressants"],"prefix":"10.1001","volume":"5","author":[{"given":"Anthony D.","family":"Bai","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Queen\u2019s University, Kingston, Ontario, Canada"},{"name":"Department of Health Research Methods, Evidence & Impact, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"McKenna","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, Kingston Health Sciences Centre, Kingston, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Wise","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, Kingston Health Sciences Centre, Kingston, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Loeb","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence & Impact, McMaster University, Hamilton, Ontario, Canada"},{"name":"Division of Infectious Diseases, Department of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeep S.","family":"Gill","sequence":"additional","affiliation":[{"name":"Division of Geriatric Medicine, Department of Medicine, Queen\u2019s University, Kingston, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,12,19]]},"reference":[{"issue":"1","key":"zoi221341r1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11908-002-0063-6","article-title":"The oxazolidinones.","volume":"4","author":"Evans","year":"2002","journal-title":"Curr Infect Dis Rep"},{"issue":"12","key":"zoi221341r2","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1517\/17425255.2015.1098617","article-title":"Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones.","volume":"11","author":"Douros","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"11","key":"zoi221341r4","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1056\/NEJMra041867","article-title":"The serotonin syndrome.","volume":"352","author":"Boyer","year":"2005","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi221341r5","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1345\/aph.1R386","article-title":"Clinical relevance of linezolid-associated serotonin toxicity.","volume":"47","author":"Woytowish","year":"2013","journal-title":"Ann Pharmacother"},{"issue":"2","key":"zoi221341r7","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00228-020-02990-1","article-title":"Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic\/pharmacodynamic analysis.","volume":"77","author":"Gatti","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"zoi221341r8","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1086\/503839","article-title":"Serotonin toxicity associated with the use of linezolid: a review of postmarketing data.","volume":"42","author":"Lawrence","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"2","key":"zoi221341r9","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1093\/jac\/dkr467","article-title":"Comparison of serotonin toxicity with concomitant use of either linezolid or comparators and serotonergic agents: an analysis of phase III and IV randomized clinical trial data.","volume":"67","author":"Butterfield","year":"2012","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"zoi221341r10","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1097\/JCP.0000000000000751","article-title":"Incidence of serotonin syndrome with combined use of linezolid and serotonin reuptake inhibitors compared with linezolid monotherapy.","volume":"37","author":"Karkow","year":"2017","journal-title":"J Clin Psychopharmacol"},{"issue":"10","key":"zoi221341r12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001885","article-title":"The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement.","volume":"12","author":"Benchimol","year":"2015","journal-title":"PLoS Med"},{"issue":"5","key":"zoi221341r14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"19","key":"zoi221341r15","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race.","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi221341r16","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1176\/ajp.148.6.705","article-title":"The serotonin syndrome.","volume":"148","author":"Sternbach","year":"1991","journal-title":"Am J Psychiatry"},{"issue":"9","key":"zoi221341r17","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/qjmed\/hcg109","article-title":"The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity.","volume":"96","author":"Dunkley","year":"2003","journal-title":"QJM"},{"issue":"6","key":"zoi221341r18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.4088\/PCC.09r00853","article-title":"Linezolid and serotonin syndrome.","volume":"11","author":"Quinn","year":"2009","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"8","key":"zoi221341r19","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I","article-title":"Interval estimation for the difference between independent proportions: comparison of eleven methods.","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"issue":"20","key":"zoi221341r20","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1002\/sim.3854","article-title":"The performance of different propensity-score methods for estimating differences in proportions (risk differences or absolute risk reductions) in observational studies.","volume":"29","author":"Austin","year":"2010","journal-title":"Stat Med"},{"issue":"1","key":"zoi221341r21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/sim.1589","article-title":"Effects and non-effects of paired identical observations in comparing proportions with binary matched-pairs data.","volume":"23","author":"Agresti","year":"2004","journal-title":"Stat Med"},{"key":"zoi221341r23","article-title":"MatchIt: nonparametric preprocessing for parametric causal inference.","author":"Stuart","journal-title":"J Stat Softw"},{"key":"zoi221341r24","doi-asserted-by":"crossref","first-page":"53","DOI":"10.32614\/RJ-2010-008","article-title":"Two-sided exact tests and matching confidence intervals for discrete data.","volume":"2","author":"Fay","year":"2010","journal-title":"R J"},{"issue":"9467","key":"zoi221341r25","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S0140-6736(05)61024-0","article-title":"Misleading use of risk ratios.","volume":"365","author":"Stadel","year":"2005","journal-title":"Lancet"},{"issue":"3","key":"zoi221341r26","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies.","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"zoi221341r3","unstructured":"US Food and Drug Administration. Zyvox. Package insert. Pfizer. 2008. Accessed December 4, 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/021130s016,021131s013,021132s014lbl.pdf"},{"key":"zoi221341r6","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: updated information about the drug interaction between linezolid (Zyvox) and serotonergic psychiatric medications. Accessed December 4, 2021. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-updated-information-about-drug-interaction-between-linezolid-zyvox-and"},{"key":"zoi221341r11","unstructured":"Institute for Clinical Evaluative Sciences. ICES data. Accessed December 31, 2021. https:\/\/www.ices.on.ca\/Data-and-Privacy\/ICES-data"},{"key":"zoi221341r13","unstructured":"Government of Ontario. Sandoz Linezolid. Queen\u2019s Printer for Ontario. 2021. Accessed December 4, 2021. https:\/\/www.formulary.health.gov.on.ca\/formulary\/detail.xhtml?drugId=02422689"},{"key":"zoi221341r22","unstructured":"Signorell? A, Aho? K, Alfons? A, . DescTools: tools for descriptive statistics. R package, version 2021:0.99.40. Accessed August 19, 2022. https:\/\/cran.r-project.org\/package=DescTools"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2799688\/bai_2022_oi_221341_1670855969.13129.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T16:33:17Z","timestamp":1671467597000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2799688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,19]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.47426","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,19]]}}}